(Q53619316)

16 May 2018

title

The therapeutic potential of PDE4 inhibitors. (English)

1 reference

16 May 2018

author name string

Dyke HJ

series ordinal

1

1 reference

16 May 2018

Montana JG

series ordinal

2

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 September 1999

1 reference

16 May 2018

Expert Opinion on Investigational Drugs

published in

1 reference

16 May 2018

volume

8

1 reference

16 May 2018

issue

9

1 reference

16 May 2018

page(s)

1301-1325

1 reference

16 May 2018

Phosphorylation-Dephosphorylation of Enzymes

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Diversity in cyclic nucleotide phosphodiesterase isoenzyme families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Molecular mechanisms of antiasthma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Sorting out the cytokines of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Leukotrienes as therapeutic target in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Relationships between adenosine, cyclic nucleotides, and xanthines in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Mechanism for the emetic side effect of xanthine bronchodilators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

KF19514, a phosphodieterase 4 and 1 inhibitor, inhibits PAF-induced lung inflammatory responses by inhaled administration in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Substituted 1,8-naphthyridin-2(1H)-ones as selective phosphodiesterase IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Pulmonary rehabilitation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Evidence-Based Health Policy---Lessons from the Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

PDE isoenzymes as targets for anti-asthma drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Rheumatoid arthritis. Pathophysiology and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Clinical management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Allergic and immunologic skin disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Aryl sulfonamides as selective PDE4 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Papaverine and Ro 20-1724 Inhibit Cyclic Nucleotide Phosphodiesterase Activity and Increase Cyclic AMP Levels in Psoriatic Epidermis In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Ro 20-1724: An Agent that Significantly Improves Psoriatic Lesions in Double-Blind Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

MS: a localized immune disease of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Tumor necrosis factor alpha induces adhesion molecule expression on human fetal astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Anti?tumor necrosis factor therapy abrogates autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

A controlled trial of azathioprine in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Inhibition of lipopolysaccharide-induced bowel erythrocyte extravasation in rats, and of mesenteric hypoperfusion in dogs, by phosphodiesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Chronic exposure to Ro20-1724 protects dopaminergic neurons in vitro against the neurotoxic action of N-methyl-D-aspartate and 1-methyl-4-phenylpyridinium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.9.1301

10.1517/13543784.8.9.1301

21 January 2018

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018